Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 16, 2007

Introgen Receives European Certification of its Production Facilities

  • Gendux and Introgen Therapeutics say that they have been given the go ahead to produce its drug candidate for a variety of somatic and inherited cancer indications.

     

    Introgen received certification from the U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) and its facilities and production processes were found to be compliant with European Good Manufacturing Practices for the production of Advexin® p53 therapy.

     

    After an audit and inspection of Introgen’s facilities, clinical certification by the MHRA was obtained so that Advexin can be made available to cancer patients in the E.U. Introgen will supply Gendux and its European marketing partners with Advexin.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »